

Acne-like Eruptions: Disease Features and Differential Diagnosis

Parać, Ena; Špiljak, Bruno; Lugović-Mihić, Liborija; Bukvić Mokos, Zrinka

Source / Izvornik: **Cosmetics, 2023, 10**

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.3390/cosmetics10030089>

Permanent link / Trajna poveznica: <https://urn.nsk.hr/urn:nbn:hr:127:281206>

Rights / Prava: [Attribution 4.0 International](#)/[Imenovanje 4.0 međunarodna](#)

Download date / Datum preuzimanja: **2025-03-11**



Repository / Repozitorij:

[University of Zagreb School of Dental Medicine
Repository](#)



Review

Acne-like Eruptions: Disease Features and Differential Diagnosis

Ena Parać ¹, Bruno Špiljak ², Liborija Lugović-Mihić ^{2,3} and Zrinka Bukvić Mokos ^{4,*}¹ Clinical Hospital Sveti Duh, 10000 Zagreb, Croatia; enaparc7@gmail.com² School of Dental Medicine, University of Zagreb, 10000 Zagreb, Croatia; bruno.spiljak@gmail.com (B.Š.); liborija@sfzg.hr (L.L.-M.)³ Department of Dermatovenereology, University Hospital Center Sestre Milosrdnice, 10000 Zagreb, Croatia⁴ Department of Dermatology and Venereology, School of Medicine, University Hospital Centre Zagreb, University of Zagreb, Kišpatićeva 12, 10000 Zagreb, Croatia

* Correspondence: zrinka.bukvic.mokos@kbc-zagreb.hr

Abstract: The term “acne-like eruptions” encompasses a variety of skin conditions resembling acne vulgaris. While both acne-like dermatoses and true acne are frequently observed in clinical settings, differentiating between the two might be challenging. Similar to acne, the lesions of acne-like eruptions may exhibit papules, pustules, nodules, and cysts. However, contrary to acne, comedones are uncommon but may still be observed in certain types of acne-like eruptions. Moreover, acne-like eruptions can be differentiated from acne based on their sudden onset, the propensity to occur across all age groups, the monomorphic appearance of lesions, and the distributions extending outside the seborrheic regions. The development of acne-like eruptions cannot be attributed to a single underlying mechanism; nevertheless, various factors such as patient age, infections, occupation, habits, cosmetics, and medications may be involved. The observed lesions may not respond to standard acne therapy, necessitating that treatment strategies are tailored in accordance with the identified causative agents. The following review aims to outline distinct entities of acne-like eruptions and present features that set them apart from true acne. Acne-like eruptions in the adult population, infectious diseases resembling acne, and acne-like eruptions resulting from exposure to chemical and physical agents are addressed in this paper. An understanding of the clinical presentation, pathophysiology, and epidemiology of this group of dermatoses is pivotal for a precise diagnosis and provision of appropriate care.

Keywords: acne; acneiform eruptions; acne-like lesions; inflammatory reaction**Citation:** Parać, E.; Špiljak, B.;

Lugović-Mihić, L.; Bukvić Mokos, Z.

Acne-like Eruptions: Disease

Features and Differential Diagnosis.

Cosmetics **2023**, *10*, 89. [https://](https://doi.org/10.3390/cosmetics10030089)doi.org/10.3390/cosmetics10030089

Academic Editor: Enzo Berardesca

Received: 7 May 2023

Revised: 5 June 2023

Accepted: 5 June 2023

Published: 8 June 2023

**Copyright:** © 2023 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article

distributed under the terms and

conditions of the Creative Commons

Attribution (CC BY) license ([https://](https://creativecommons.org/licenses/by/4.0/)[creativecommons.org/licenses/by/](https://creativecommons.org/licenses/by/4.0/)

4.0/).

1. Background

Acne represents the most widely prevalent skin disorder worldwide [1]. This chronic inflammatory condition impacts the pilosebaceous unit, with a predilection for regions containing densely distributed sebaceous glands, as seen on the face, upper chest, back, and neck [2]. The follicular lesion characteristic of acne is the result of a complex interplay of various factors and may present with a comedo, papule, pustule, nodule, or cyst [3]. The global prevalence of acne is estimated at 9.4% among the population [4], ranking as the eighth most encountered disease on a global scale [5]. Due to its substantial presence, it is not uncommon for other cutaneous disorders that share similarities with acne to be misidentified as such. Such dermatoses bearing resemblance but not related to genuine acne vulgaris are referred to as “acneiform eruptions” or, more recently, “acne-like eruptions” [6]. Acne-like eruptions are a group of many skin disorders exhibiting papules, pustules, nodules, or cysts where, compared to acne, the occurrence of comedones is less frequent. They may be caused by a wide variety of factors, including infections, medications, genetic disorders, and hormonal and metabolic imbalances. Due to the discrepancy in the literature regarding the term “acneiform eruptions” [7–9] and the diagnoses that fall under it [8,10,11],

for the scope of this paper, we will refer to acne-like eruptions throughout the article. In this narrative review, we will present different entities of acne-like eruptions by classifying them into three main groups. By categorizing them according to age and offending agents, this translates to acne-like eruptions in the adult population, infectious diseases resembling acne, and acne-like eruptions due to chemical and physical agents.

2. Acne-like Eruptions in the Adult Population

Various lesions sharing common features with acne can present in adulthood. Most dermatoses presented in the following chapter display high prevalence rates and, as such, should be included in the differential diagnosis when evaluating patients with lesions resembling acne. Recognition of the characteristic and distinguishing clinical features of these eruptions can facilitate the correct diagnosis.

2.1. Rosacea

Rosacea is a chronic, relapsing, and prevalent inflammatory condition primarily involving the convex central facial with acne-like papules, pustules, erythema, and telangiectases. Although a wide array of presentations is possible, rosacea typically affects fair-skinned individuals, the majority of whom are females over the age of 40 [12,13]. The pathophysiology has not been fully elucidated, but an individual's genetic profile, environmental factors, neurogenic inflammation, vascular hyperreactivity, and alterations in immune response all appear to have a contributory role (Figure 1) [14]. Moreover, although a number of studies suggest an association between rosacea and the skin and gut microbiota, it remains uncertain whether altered microbiota and dysbiosis initiate inflammation or if they are consequential effects of changes in the skin microenvironment [14–16]. Unlike acne vulgaris, rosacea does not display comedones or seborrhea, it is a relapsing disorder with a symmetrical facial distribution, and it may be accompanied by secondary features such as stinging, burning, edema, dryness, and ocular manifestations [17]. Different therapeutic techniques may be used to control the relapsing nature of the disease. This may include trigger avoidance, topical agents (such as brimonidine tartrate, ivermectin, azelaic acid, and metronidazole), oral antibiotics, vascular lasers, and light-based therapies [11,18].




Figure 1. Factors implicated in the pathogenesis of rosacea (a modified scheme based on Parać E. [19]). Created with <https://www.biorender.com/>, (accessed on 2 May 2023). Abbreviations: ADM—Adrenomedullin; BTNL2—Butyrophilin-like 2; CGRP—Calcitonin Gene-Related Peptide; GST—Glutathione-S-Transferase; HLA-DRA—Human Leukocyte Antigen-DRA; KLK5—Kallikrein 5; LL-37—Cathelicidin Antimicrobial Peptide; MMPs—Matrix Metalloproteinases; PACAP—Pituitary Adenylate Cyclase-Activating Polypeptide; SNP—Single-Nucleotide Polymorphisms; TRPs—Transient Receptor Potential (TRP) Cation Channels; VIP—Vasoactive Intestinal Peptide; ↑—increased; ↓—decreased.

2.2. Demodicosis

Demodex mite is an obligatory ectoparasite that dwells in or in close proximity to the hair follicle. While skin colonization with these mites does not usually elicit any symptoms, they may lead to detrimental effects when in significant numbers [20,21]. An excessive population of *Demodex* parasitic mites responsible for human demodicosis can be attributed to various conditions, including end-stage renal disease, immunodeficiencies, obesity, and diabetes mellitus [22–24]. Furthermore, an increase in their density has been demonstrated following the prolonged use of topical corticosteroids [25]. Since demodicosis can mimic other dermatological conditions, it is frequently underdiagnosed and misdiagnosed [26]. Demodicosis may be classified into four clinical forms, each of which is named after the skin condition it resembles; rosacea type, perioral type, pityriasis folliculorum, and acne type. The latter clinically imitates acne vulgaris and presents with localized, non-scaly follicular pustules. The determination of mite density can be conducted through direct microscopic examination or standardized skin surface biopsy [20]. Treatment options include topical and systemic ivermectin, topical and systemic metronidazole, and topical and light therapy, such as intense pulsed light (IPL) [11,27].

2.3. Perioral Dermatitis

Perioral (periorificial) dermatitis (PD) is a common acne-like facial dermatosis that primarily afflicts individuals with fair complexion, particularly women aged 15 to 45. Classic PD presents with many 1 to 2 mm large papules and pustules situated on discernible erythema of the perioral region. The narrow zone surrounding the vermilion border is typically spared [28,29]. The etiopathogenesis of this condition has yet to be established. Nevertheless, apart from the well-documented relationship between PD and topical corticosteroids, ongoing research is investigating the potential involvement of hormones, ultraviolet light, skin irritants, and microbiological agents in the formation of PD lesions [28]. Furthermore, epidermal barrier dysfunction can exacerbate PD. The occurrence of lesions may additionally be associated with secondary deficiencies of vitamins or minerals, the use of sunscreen, and excessive exposure to environmental factors such as wind and heat (Figure 2) [30]. The choice of treatment is contingent upon the state and extent of the disease. It includes “zero therapy”, i.e., complete withdrawal of offending agents, topical metronidazole, azelaic acid, erythromycin, and pimecrolimus, or in severe disease forms, oral tetracyclines [28,29].




Figure 2. Proposed etiopathogenic factors in the development of perioral dermatitis (an original scheme reproduced from Parać E. [19]). Created with <https://www.biorender.com/> (accessed on 2 May 2023).

2.4. Hidradenitis Suppurativa

Hidradenitis suppurativa (HS), also known as acne inversa, is a debilitating chronic inflammatory skin disorder that affects the pilosebaceous units of the apocrine-gland-rich intertriginous areas of the body. It presents with tender and deep papular, pustular, or nodular lesions, or abscesses, which may progress and form sinus tracts and scars. The onset of HS generally occurs in the early stages of adulthood and can be attributed to different environmental and genetic factors. Among the proposed risk factors, smoking and obesity are the most significant ones associated with the disease. HS has been linked to several accompanying conditions, such as autoinflammatory syndromes, inflammatory bowel disease, spondyloarthritis, and metabolic syndrome, as well as other disorders of follicular occlusion, particularly conglobate acne [31–33]. Due to the characteristic painful and odorous lesions, patients afflicted with HS commonly report psychological disturbances and impaired quality of life [34]. The Hurley staging system is used to stratify patients into three stages in accordance with the disease severity. Hurley stage I, particularly when accompanied by acne as comorbidity or when observed in ectopic sites, should be considered in the differential diagnosis of acne-like eruptions. One of the

characteristic clinical signs of HS is the presence of double- or multiple-ended comedones, also known as “tombstone” comedones. Various treatment options are available for HS lesions (Figure 3) [35,36].

MANAGEMENT OF HIDRADENITIS SUPPURATIVA		
HURLEY I	HURLEY II	HURLEY III
Solitary or multiple abscesses, without sinus tracts or scars	Recurrent single or multiple abscesses, with sinus tracts and scars	Diffuse involvement, multiple interconnected sinus tracts and abscesses
Smoking cessation, BW reduction, wearing loose clothing to avoid friction on the skin		
		Antiseptic to reduce odour
Provide health education for self-management, refer for psychosocial support		
Topical antibiotics: clindamycin		
Intralesional steroids		
Zinc gluconate		
Systemic antibiotics: tetracyclines		
		Systemic antibiotics: clindamycin + rifampicin
		TNF - α inhibitors: adalimumab
Local procedures for nodules and abscesses		
		Local procedures for sinus tracts
		Radical wide excision

Figure 3. Treatment recommendations for hidradenitis suppurativa based on the Hurley staging system (an original scheme reproduced from Parać E. [19]). Created with <https://www.biorender.com/> (accessed on 2 May 2023). Abbreviation: BW—body weight.

2.5. Pseudofolliculitis Barbae

Pseudofolliculitis barbae (PFB) is an inflammatory condition of the hair follicle presenting with erythematous papules and pustules that may occur in any site where hair is shaved or plucked. The lesions predominantly occur on the face and neck of men due to shaving. Interestingly, the moustache area is typically unaffected [37,38]. PFB is more commonly seen in populations with tightly curled, coarse hair, due to the specific hair morphology that causes emerging hairs to penetrate epidermal and dermal skin layers, creating extra-follicular or intra-follicular lesions, respectively [37,38]. The eruptions are quite similar to those of acne vulgaris, but the absence of comedones is the crucial distinguishing feature of PFB [39]. The primary focus of treatment is to halt all hair removal methods to facilitate the resolution of the inflammatory response. Nevertheless, painful, pruritic, or more advanced lesions may require specific measures. Topical clindamycin, benzoyl peroxide, steroids, keratolytic agents, and triamcinolone injections have proven to be effective [37,40]. The definite treatment method entails the removal of the hair follicles, where laser and intense pulsed light (IPL) depilation are effective and convenient options [41]. These systems employ different wavelengths to selectively target specific chromophores, in this case, melanin, resulting in the destruction of the follicle. Its application in individuals with darker skin had previously been limited due to concerns about post-inflammatory hyperpigmentation and scarring. Nowadays, laser devices that employ longer wavelengths, such as the long-pulsed diode laser (810 nm) and the neodymium: yttrium aluminium garnet (Nd:YAG) laser (1064 nm) are suitable for these patients, as they reach the root of the follicle while having minimal impact on the epidermal melanin [37,40,41].

2.6. Eosinophilic Pustular Folliculitis

Eosinophilic pustular folliculitis (EPF), also termed Ofuji disease, is a rare, non-infectious inflammatory skin condition presenting with papulopustules, whose distinctive histological feature is the presence of eosinophilic infiltrates surrounding the pilosebaceous unit. The disease can be divided into three variants: immunosuppression-associated EPF (IS-EPF), infancy-associated EPF (I-EPF), and classic EPF. The latter variant was initially documented by Ofuji in 1970 in Japan, and it still continues to be predominantly observed among Japanese individuals. It develops in seborrheic regions of otherwise healthy individuals, with papular and pustular lesions that merge into plaques and may be accompanied by pruritus [42,43]. Conversely, the most frequently encountered EPF eruption is IS-EPF, which primarily affects HIV-infected patients. A hallmark feature of IS-EPF is extreme and persistent pruritus accompanying the lesions, resulting in frequently severely excoriated papules and pustules [44]. Given the recurrent nature and unknown pathogenesis of EPF, finding an effective therapeutic approach is challenging. While topical steroids may be the attempted first-line treatment for all disease variants, a definitive regimen is tailored according to the specific EPF variant [42–44].

2.7. Sarcoidosis

Sarcoidosis is a multiorgan granulomatous disease of an unknown origin, notably presenting with pulmonary manifestations [45]. However, among extrapulmonary manifestations, the skin is one of the most commonly affected organs; up to one third of patients present with skin involvement [46]. Different types of skin lesions are associated with sarcoidosis, and they are grouped into “specific” or “non-specific” lesions based on the presence or absence of distinctive sarcoidotic granulomas [45]. Among specific lesions, maculopapular eruptions predominate. These monomorphic lesions are typically located on the face and present with small papules that may coalesce into annular lesions or plaques. In contrast to acne vulgaris, comedones and pustules are absent in sarcoid lesions [45,47].

2.8. Papular Granuloma Annulare

Granuloma annulare (GA) is a common inflammatory dermatological disorder that frequently presents with annular plaques consisting of intradermal papules. The localized variant of GA is the most commonly observed type, and most often, it manifests with a ringed lesion [48,49]. Conversely, the less typical papular presentation of GA lacks the characteristic ring and hence may be misinterpreted as an acne eruption. However, acne can be excluded due to dissimilar affected areas, no epidermal change, the absence of comedones and pustules, and a uniform morphology of GA lesions when compared to acne [50]. GA can appear at any age; nevertheless, it is predominantly observed in children and young adults, with a twofold higher incidence in females compared to males. The lesions are typically located on the extremities [48,51]. Despite the uncertain etiology, GA has been linked to viral infections, malignancies, thyroid disease, hyperlipidemia, trauma, and certain drugs [48,52]. In most cases, the eruption is asymptomatic and may exhibit a self-limiting course over time. However, since GA can demonstrate a relapsing nature, topical steroids or intralesional triamcinolone injections may be employed as a treatment modality [49,53].

2.9. Periorificial Granulomatous Dermatitis

Periorificial granulomatous dermatitis (PGD) is interchangeable with Gianotti-type perioral dermatitis, childhood granulomatous periorificial dermatitis, and facial Afro-Caribbean childhood eruption (FACE) [11]. This condition is quite rare, and most cases are observed in prepubertal children, although cases in adults have also been identified [54–56]. The etiology of this eruption is still undetermined. A common assumption is that PGD is a less frequent and granulomatous variant of perioral/periorificial dermatitis (PD) and that the two conditions share the same underlying causes [54,57]. PGD presents with isolated monomorphous 1 to 3 mm large dome-shaped papules that are typically

asymptomatic. The hue of the lesions may vary from pink-red to flesh-colored to yellow-brown [54]. PGD consistently involves the face, where papules are chiefly located in the perioral, periorbital, and perinasal regions [57,58]. The involvement of the vermilion border in PGD distinguishes it from other conditions, providing a helpful differentiation from PD [55]. Moreover, PGD is different from acne due to the monomorphous papules, absence of pustules or comedones, perioral placement of lesions, self-limiting character, and the distinctive histology of the disease [11]. Histologically, PGD is characterized by perifollicular noncaseating granulomas with lymphohistiocytic infiltrates. PGD generally exhibits a relatively benign clinical course, with spontaneous resolution occurring over several months or years. To date, no instances of systemic involvement have been reported. Therapeutic intervention is generally not necessary, although topical and oral antibiotics, as well as topical calcineurin inhibitors, could be employed to hasten the resolution process. Nevertheless, it is crucial to carefully consider the benefits of these medications in relation to their potential adverse effects [57,58].

Figure 4 summarizes some of the aforementioned differential diagnoses of acne-like eruptions.

Condition	Common feature	Distinguishing feature
Rosacea	Common and chronic inflammatory disorder, presents with inflammatory papules and pustules that affect the face	No comedone formation, centropacial involvement, presence of ocular symptoms, episodic occurrence, flushing, telangiectasias, triggers cause flare-ups
Periorificial granulomatous dermatitis	Erythematous or flesh-colored papular eruption that involves the face, can involve the vermilion border, no systemic involvement	Mainly affects African Americans, lesions concentrated around the mouth, nose, eyes, presence of monomorphic papules, absence of comedones and pustules, lesions may become confluent
Periorificial dermatitis	Common skin eruption, erythematous papules and pustules affect the face	No comedones present, no extrafacial eruptions, spares the vermilion border, spares the jawline, cheeks, forehead, itching or burning sensation often reported, most common in young women, may be triggered by steroid use
Sarcoidosis	Erythematous or flesh-colored papules, may affect the face and the neck	Multisystem involvement, presence of systemic symptoms, onset usually after puberty, more common in African Americans and Scandinavians, presence of monomorphic papules; may coalesce into annular lesions or plaques, absence of comedones and pustules, papules may be accompanied by other specific and non-specific lesions of cutaneous sarcoidosis
Demodicosis	Erythematous facial papules and pustules	Immunocompromised host, acaricidal therapies effective, sandpaper-like appearance, scaling, itching, <i>Demodex</i> infestation of eyelash hair follicles results in blepharitis, madarosis and ocular irritation

Figure 4. Comparison of certain acne-like eruptions with acne vulgaris (an original scheme reproduced from Parać E. [19]). Created with <https://www.biorender.com/> (accessed on 3 May 2023).

3. Infectious Diseases Resembling Acne

The overgrowth of infectious agents, such as *Staphylococcus aureus*, *Pseudomonas aeruginosa*, and *Malassezia furfur*, is commonly implicated in the appearance of acne-like lesions. The diagnosis of the following eruptions is mainly clinical, although confirmation by culture or microscopic examination is possible. Treatment is directed at the organism in question, although some lesions display a self-limiting nature.

3.1. Bacterial Folliculitis

Folliculitis is a common skin disorder characterized by an inflammatory process involving the hair follicle, affecting either the perifollicular region or the follicular opening. The prevailing form of folliculitis is bacterial folliculitis, and *Staphylococcus aureus* is the primary causative agent [59]. Several factors predispose to increased bacterial skin colonization, namely, the nasal carriage of *Staphylococcus aureus*, exposure to chemicals and oils, and occlusion [60]. Additional risk factors include follicular unit manipulation by means of plucking, shaving, or waxing, as well as residing in tropical climates. It is difficult to determine the true incidence of bacterial folliculitis given that many affected individuals do not request medical assistance. This condition may be divided into two distinct clinical types based on the degree of hair follicle involvement. The predominant form of bacterial folliculitis is known as superficial bacterial folliculitis or Bockhart impetigo. It affects the superficial portion of the hair follicle, manifesting as minute folliculocentric pustular eruptions enclosed by erythema which eventually transform into crusted papules. Pruritus and pain are common accompanying symptoms. On the other hand, deep folliculitis arises when the hair follicle is entirely affected. It is characterized by furuncles that initially begin as aching inflammatory nodules and evolve into necrotic lesions in a matter of days [60,61]. Young adult males, diabetics, and immunocompromised patients are more likely to experience furuncles [62]. The management of bacterial folliculitis should target the most likely causative bacteria or the bacteria detected by culture [61].

3.2. Gram-Negative Folliculitis

Gram-negative folliculitis is a follicular pyoderma that arises as a complication of prolonged use of oral antibiotics, among which tetracyclines are most commonly implicated [63]. Oral antibiotic therapy leads to a shift in the composition of the normal skin microflora, causing a decrease in the population of resident Gram-positive microorganisms, namely, *Staphylococcus aureus* and diphtheroids. Conversely, the quantity of Gram-negative rods such as Enterobacteriaceae correspondingly increases in the nasal mucosa and the adjacent skin. Depending on the particular culprit agents involved, this can lead to the development of either papulopustular lesions (type I) or deep cystic lesions (type II) [64]. Typically, the lesions are localized in the infranasal region and have the potential to extend to the cheeks and chin. Even though the detection of Gram-negative folliculitis is not frequent, it is probably under-reported due to the potential misdiagnosis as an acne exacerbation. Hence, clinicians should consider Gram-negative folliculitis in patients with acne who experience a worsening of pustular or cystic lesions while on antibiotics, and in individuals who fail to see significant improvement in their acne after 3 to 6 months of antibiotic therapy. The preferred treatment for Gram-negative folliculitis is isotretinoin due to its ability to reduce sebum production, thereby creating an unfavorable environment for Gram-negative organisms [63,64].

3.3. Malassezia Folliculitis

Malassezia folliculitis (MF), formerly termed Pityrosporum folliculitis, is an infectious follicular papulopustular eruption on the torso, face, and upper extremities of young to middle-aged adults. The condition is attributed to yeasts of the *Malassezia* genus, which are normal skin commensal organisms [65]. The yeasts are lipophilic, so they thrive in the sebaceous-rich environment of hair follicles. Consequently, 90% of people harbor them in their hair follicles and stratum corneum [66]. *Malassezia* yeasts have been associated

with other common dermatological ailments such as pityriasis versicolor and seborrheic dermatitis. Additionally, *Malassezia* species worsen the head and neck variant of atopic dermatitis and have recently been proposed to contribute to psoriasis [65,67]. MF frequently develops in young individuals due to increased sebum production in those who have taken broad-spectrum antibiotics resulting in changes in their skin microbiota, and in immunocompromised patients. In such circumstances, the commensal yeast *Malassezia furfur* overgrows and becomes pathogenic [65]. Even though MF is prevalent, it is generally underdiagnosed since it is commonly misinterpreted as acne vulgaris. Contrary to true acne, lesions observed in MF are monomorphic and pruritic, lack comedones, and are responsive to empiric antifungal therapy instead of antibiotics (Figure 5). The diagnosis of the condition is primarily clinical, but confirmation may be achieved by microscopic examination using potassium hydroxide and skin biopsy [68]. The primary modality of therapy remains oral antifungal medications, with topical treatment occasionally required to prevent recurrences [66,67].

	Acne vulgaris	Malassezia folliculitis
Etiology	Increased sebum production and follicular hyperkeratinization	Overgrowth of skin commensal <i>Malassezia furfur</i>
Lesion Characteristics	Polymorphic lesions with open and closed comedones, inflammatory papules and pustules, as well as nodules and cysts	Monomorphic papular and pustular lesions that lack comedones, frequently pruritic
Localization	Face, neck, upper chest, back	Back, chest, upper arms
Treatment	Benzoyl peroxide, topical retinoids, topical antibiotics, oral antibiotics, isotretinoin, hormonal therapy	Unresponsive to or aggravated by acne treatment Treated with oral antifungal medications

Figure 5. Differences between acne vulgaris and *Malassezia folliculitis* (an original scheme reproduced from Parać E. [19]). Created with <https://www.biorender.com/> (accessed on 3 May 2023).

3.4. Hot Tub Folliculitis

Hot tub folliculitis, alternatively known as *Pseudomonas folliculitis*, is a follicular infection brought on by the Gram-negative opportunistic pathogen *Pseudomonas aeruginosa* (*P. aeruginosa*). This ubiquitous bacterium is present in freshwater and soil, and can enter the body through skin breaks and hair follicles. The probability of water being contaminated with *P. aeruginosa* increases in warm, alkaline, or insufficiently chlorinated water. Once the bacterium has reached the skin, it appears that showering does not prevent *Pseudomonas folliculitis*. The lesions mostly emerge within one to four days following exposure to contaminated whirlpools, hot tubs, or swimming pools. The characteristic pruritic rash initially presents with follicular macules which progress into papules and pustules. A pinpoint vesicle is found in the central area of the lesion. The rash is more commonly found in intertriginous areas or under bathing suits due to the compression of contaminated water in such locations. Other minor symptoms, such as fever, malaise, sore throat, and earache, may be reported, but systemic infection is rare. Without any intervention, the lesions typically resolve spontaneously within 7 to 14 days [69–71].

3.5. Sporotrichosis

Sporotrichosis is a mycotic skin infection caused by *Sporothrix schenckii* (*S. schenckii*), a saprophytic fungus that commonly colonizes plants. The infection primarily afflicts gardeners and agricultural workers, usually due to minor injuries with contaminated material. The fungus gains entry into the body through small wounds and abrasions in the skin. In the majority of cases, *S. schenckii* causes a lymphocutaneous infection [72,73]. Nevertheless, it may potentially present in a fixed cutaneous form [74]. In instances of papulonodular eruptions, it may be mistaken for acne. Culture of tissue specimens is the preferred diagnostic method. Antifungal drugs, such as itraconazole, constitute the mainstay of therapy [73–75].

3.6. Cutaneous Coccidioidomycosis

Coccidioidomycosis originates from two distinct soil-borne fungi of the Coccidioides genus, *Coccidioides posadaei* and *Coccidioides immitis*. This fungal infection exhibits a wide range of clinical manifestations, varying from asymptomatic cases to severe and disseminated forms. The most common clinical presentation of the disease is primary pulmonary coccidioidomycosis, while cutaneous involvement is one of the most common extrapulmonary manifestations of coccidioidomycosis. Cutaneous coccidioidomycosis can present in three different manners: as an exanthem linked with pulmonary coccidioidomycosis, as a secondary cutaneous infection in disseminated disease, or, infrequently, as a primary cutaneous infection from the direct fungal inoculation. Given the vast array of clinical manifestations, cutaneous coccidioidomycosis may be categorized under “great imitators” [76]. Cutaneous lesions could appear as singular or multiple papulonodules, pustules, abscesses, ulcers, or scars. When observing the aforementioned lesions in patients residing in Coccidioides-endemic regions, clinicians should be prompted to consider coccidioidomycosis in their differential diagnosis. Confirmation of the diagnosis typically relies on histological examination or fungal isolation [77]. Antifungal medications are employed to treat the condition [76].

3.7. Secondary Syphilis

Secondary syphilis is a systemic condition that results from the hematogenous dissemination of *Treponema pallidum*. It usually appears between 2–8 weeks following the emergence of the primary chancre. Various cutaneous manifestations of secondary syphilis have been documented, among which acne-like eruptions may also be evident. The clinical presentation typically includes nodules and crusted papules and pustules situated on the trunk, extremities, and face. The lesions are commonly accompanied by concurrent systemic symptoms, including fever, lymphadenopathy, and general malaise. Given syphilis' designation as “the great mimicker”, it is essential to consider it in the differential diagnosis when evaluating any widespread skin eruption. The diagnosis is established through serologic tests and visualization of spirochetes by dark-field microscopy. Penicillin is the preferred treatment option [78,79].

4. Acne-like Eruptions Resulting from Exposure to Chemical and Physical Agents

Exposure to different chemical and physical agents may lead to the formation of eruptions closely resembling acne vulgaris. However, although clinically similar, any follicle in the body besides the sebaceous follicles can be affected. The eruptions typically present in the skin regions that are in contact with the chemical or physical agent in question. Besides specific treatment, some eruptions show improvement upon elimination of the provoking factors.

4.1. Acne Aestivalis

Acne aestivalis, also known as Mallorca acne, is a seasonal and monomorphous skin eruption that develops following exposure to sunlight [80]. The term “Mallorca acne” was first introduced in the 1970s [81] after Scandinavian individuals, who had vacationed in the

Mediterranean, exhibited such lesions. After a period of reduced exposure to the sun during the winter season, the subsequent encounter with high-intensity ultraviolet (UV) radiation triggered an eruption. Eventually, the significance of UV radiation, particularly ultraviolet A (UVA), along with genetic predisposition have become evident in the pathogenesis of Mallorca acne. Since these eruptions emerge during spring, peak in summer, and subside in autumn, they are also classified as polymorphic light eruptions (PLE). The lesions are characterized by uniform, small keratotic nodules, and are devoid of comedones. They are distributed across the back, upper arms, chest, and neck, while the face may be spared. Histological examination of Mallorca acne reveals notable similarities to steroid acne, as they both exhibit focal follicular destruction accompanied by infiltrates of neutrophils [63]. Furthermore, presentations resembling acne aestivalis may arise as a rare side effect of PUVA treatment [82]. The condition poses a therapeutic challenge. It is advised to avoid further sun exposure and the application of oily sunscreens. For symptomatic relief, oral antihistamines can be used, and in severe cases, exfoliating acne medications such as benzoyl peroxide and adapalene may be prescribed. There is insufficient evidence to support the use of oral antibiotics or topical glucocorticoids. Spontaneous improvement is typically observed within several months. However, similar to PLE, patients may experience a recurrence upon re-exposure to UV radiation. As a preventive measure, it is crucial to gradually expose the skin to UV radiation, use gel-based sunscreens, and prioritize staying in shaded areas during the spring and summer months. In cases where symptoms persist despite adherence to preventive measures, UV hardening can be considered during the winter months as a form of light adaptation. This involves exposing the skin to controlled doses of UV light, beginning with very low levels and gradually increasing them [63].

4.2. Acne Mechanica

Acne mechanica refers to the emergence of inflammatory papules and pustules owing to mechanical forces. The condition arises due to the chronic irritation of the pilosebaceous unit, induced by repeated friction exerted on the skin, combined with occlusion, heat, and pressure on the skin [83]. Although acne mechanica and acne vulgaris present similarly, patient history and lifestyle factors can help distinguish between the two conditions. Mechanical obstruction is a significant contributing factor in the development of acne mechanica, and it can be observed in different activities and settings. One notable example showing this phenomenon can be observed in contact sports such as American football. In fact, since acne mechanica appears in players wearing helmets, shoulder pads, and chinstraps, it has been referred to as “football acne” and “sports-induced acne” [84,85].

Moreover, acne mechanica has also been observed in equestrians who wear chinstraps [84] and in violinists whose instruments’ chin rests repeatedly rub against the skin, providing a clinical picture of “fiddler’s neck” [86]. Nonetheless, not all skin changes in areas that have been in contact with the equipment can be solely assigned to “sports-induced acne”. It is important to consider allergic contact dermatitis as a potential alternative diagnosis [84]. The treatment of acne mechanica focuses on identifying and eliminating the causative factors, as this may result in resolution without further intervention. However, in cases where it is required, topical retinoids, benzoyl peroxide, and oral antibiotics may be utilized [84,85].

4.3. Acne Cosmetica

Acne cosmetica is a term designating eruptions consisting of multiple comedones induced by the use of cosmetics. Although uncommon nowadays, acne cosmetica was widespread in the 1970s and 1980s, when comedogenic ingredients were prevalently used in cosmetic products. The occlusive nature of used products led to the development of comedones, which would sometimes be accompanied by papules and pustules [87]. Nowadays, skincare product constituents undergo extensive testing, and most agents are labeled “non-comedogenic” [11]. Nonetheless, a subtype of acne cosmetica known as pomade acne (acne venenata) is still common, particularly among individuals who use

pomades or scented ointments for their hair. Since pomades are commonly applied to the scalp and the hair, they may affect the adjacent skin areas with acne lesions, such as the temples and the forehead [87,88].

4.4. Radiation Acne

Postradiation acne-like eruptions may arise as a response to both UV and ionizing radiation. Comedo-like papules may appear on the skin regions that have received therapeutic ionizing radiation within a period of two weeks to six months following the exposure. While radiation-induced dermatitis is a significantly more common adverse effect of radiotherapy, a small proportion of treated patients may develop acne-like lesions alongside the resolution of dermatitis. Among the affected individuals, most present with radiation-induced acne on the face, scalp, or neck. The exact mechanism underlying its development remains incompletely understood. It is hypothesized that ionizing radiation may alter the composition of sebum, reduce its production, and stimulate hyperproliferation in pilosebaceous ducts [89,90]. Conversely, excessive UV radiation exposure may lead to the development of a disorder termed Favre–Racouchot syndrome (FRS). Excessive exposure to ultraviolet radiation, tobacco use, and prior radiotherapy are the most important risk factors for its occurrence [91]. FRS most typically presents in middle-aged Caucasian men with the involvement of the periorbital and malar regions. It is a prevalent dermatosis, affecting roughly 6% of adults over the age of 50. Due to the clinical and histological appearance of the lesions observed in affected individuals, the condition is also referred to as “nodular elastosis with cysts and comedones”. The most effective therapeutic approach combines protective measures, medical treatment (topical or oral retinoids), and extraction [92,93].

4.5. Chloracne

Exposure to polyhalogenated aromatic hydrocarbons can cause an uncommon but severe skin condition called chloracne [94]. These lesions belong to halogenodermas, i.e., skin eruptions associated with reactive halogen elements such as bromine, iodine, and chlorine. The mechanism behind halogenoderma is believed to involve a delayed-type hypersensitivity reaction, and the eruptions may have similar clinical features [95]. In the case of chloracne, causative agents, also known as chloracnogens, can be found in occupational and industrial settings, in addition to polluted environments. Due to the potential presence of these substances in industrial waste material and food, they may enter the human body through inhalation, ingestion, and percutaneous absorption [94,96]. Chloracne is linked to one of the most devastating anthropogenic environmental catastrophes in history. The infamous chemical factory explosion near the town of Seveso, Italy, exposed the general population to high levels of dioxins. The “ICMESA plant explosion” resulted in the release of two kilograms of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), leading to severe health consequences [97]. In Japan, there was another considerable polychlorinated hydrocarbon exposure, which led to one of the biggest food poisonings in the world. This event, known as the “Yusho” incident, resulted from the mass contamination of rice bran oil with polychlorinated hydrocarbons [98]. The detrimental effects of chloracnogens are brought about by their immune suppression, carcinogenicity, and endocrine disruption [99]. In more advanced cases, ophthalmopathy, neuropathy, and hepatic dysfunction may develop [100]. In terms of skin alterations, the most distinctive characteristic of dioxin exposure is the development of an acne-like reaction. Chloracne exhibits dissimilarities from other halogenodermas and acne vulgaris. In particular, comedones serve as a hallmark of these lesions and may be present in extensive quantities, affecting all follicles. Notably, these lesions tend to manifest in specific locations, such as the malar crescents, postauricular regions, groin, axilla, and other facial areas. However, the nose is usually unaffected; the feature that was aptly described by Tindall in 1985, when referring to it as an “island in a sea of lesions” [101,102]. In contrast to acne vulgaris, chloracne rarely shows signs of inflammation, exhibits reduced sebum production, and emerges in distinctive locations [103]. In addition to chloracne, other cutaneous manifestations may include grayish skin discol-

oration, brownish discoloration of the nails, and hypertrichosis [101]. Chloracne is a highly challenging condition to treat, and therapy outcomes are generally unsatisfactory. Retinoic acid and oral antibiotics may provide some relief, but efficacy is limited. Unfortunately, discontinuation of exposure does not result in the resolution of chloracne, and the condition may persist for a long time, up to 15–30 years thereafter [96,101].

4.6. Oil Acne

Among the types of occupational acne, oil acne stands out as the most common form. It occurs due to exposure to mineral oil, which may be found in significant amounts in solvents and greases. Individuals employed in occupations such as marine engineering, the automotive industry, and machine operation may be particularly vulnerable to oil acne as they are exposed to mineral oils that frequently soak their work attire. This exposure can result in mechanical blockage of pilosebaceous glands, forming comedones and inflammatory eruptions, which typically appear on the dorsal surface of the hands, forearms, and thighs. To prevent this condition, it is important to refrain from contact with mineral oils, regularly change clothes, and maintain good personal hygiene. The use of oral tetracyclines and retinoids has demonstrated favorable outcomes [101,104].

4.7. Coal Tar Acne

Coal tar is a viscous, dark liquid obtained as a byproduct of the coal distillation process. While its medical application is beneficial, its industrial use holds far greater importance. It is commonly employed in aluminum and steel production, roofing, and road construction [105]. Coal tar acne, which results from exposure to coal tar, has been identified in nearly 25% of workers who have been exposed to it [106]. The respiratory system, the gastrointestinal system, and the skin all serve as potential entry routes for the development of this acne variant. Accumulation of coal tar fluid in the skin, along with keratin products, can obstruct sebaceous glands and cause coal tar acne to develop on the cheeks, characterized by open comedones. This type of acne does not show inflammatory papules or yellow cysts, the absence of which distinguishes the condition from oil acne and chloracne. Moreover, coal tar acne is more responsive to treatment than chloracne. In order to decrease the incidence of coal tar acne, industry workers should take precautions, follow preventive measures, and avoid potentially hazardous levels of coal tar [101].

4.8. Drug-Induced Acne-like Eruptions

Different medications can potentially cause a condition known as acne medicamentosa, which refers to acne-like eruptions triggered by drugs. The introduction of certain drugs may form acne-like lesions or aggravate pre-existing acne. The presenting lesions are devoid of cysts and comedones, and correspondingly coincide with the introduction or discontinuation of the drug. Although a link between acne and medications has been reported for various drugs, this paper focuses on addressing acne-like eruptions in response to steroid drugs and anticancer treatments.

4.8.1. Steroid Acne

Despite an incomplete understanding of its pathogenesis, the development of acne as a result of corticosteroids has been reported for over 70 years [107]. ‘Steroid acne’ is commonly observed following the administration of high doses of either inhaled, topical, or systemic corticosteroids. These lesions typically display skin-to-pink monomorphic papules and pustules. They usually affect the trunk and the face, and may extend to the shoulder region [108]. The likelihood of patients experiencing corticosteroid-induced acne generally relies on the duration and dosage of the drug, as well as on the individual characteristics of each patient. The underlying mechanism could be attributed to either the direct effects of steroids on epithelial degeneration and inflammation [108], or an elevation in free fatty acids (FFA) in skin lipids, leading to increased bacterial levels [109]. The onset

of these eruptions can vary greatly, ranging from immediate manifestation following drug administration to several months after [108,110].

4.8.2. Epidermal Growth Factor Receptor Inhibitors

The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor that normally counteracts signaling pathways for cellular differentiation and proliferation. However, EGFR mutations result in the dysregulation of this pathway, as observed in different cancers such as colorectal, lung, and head and neck cancers. Epidermal growth factor receptor inhibitors (EGFRI) are therefore used as anticancer therapy. This group includes monoclonal antibodies targeting the extracellular domains of EGFR (such as panitumumab and cetuximab), and tyrosine kinase inhibitors targeting the intracellular domains of EGFR (such as gefitinib and erlotinib) [111]. Acne-like eruptions have emerged as a prominent side effect of EGFRI chemotherapy, as their incidence rates in treated patients vary from 53% to 100% [112]. Additionally, the degree of severity is associated with the dosage level. The appearance of skin lesions is the most commonly reported adverse effect of EGFRI, and due to the pruritic nature of presenting papulopustules, the term ‘acneiform rash’ has been introduced. This acne-like reaction is devoid of comedones and appears in seborrheic areas, with occasional involvement of the extremities, abdomen, or lower back. The rash is more frequently reported with EGFR monoclonal antibody drugs. It usually emerges following the initial treatment cycle and reaches its peak incidence between three to four weeks of therapy [113,114]. The management of EGFRI-induced lesions depends on the severity of the condition, which is evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grading system. Grade 1 eruptions can be effectively managed with topical agents such as clindamycin 2% or metronidazole 0.75%. The management of grade 2 includes topical treatment as in grade 1, but oral minocycline or doxycycline may be prescribed as well. Grade 3 may respond to the same treatment methods as grade 2, although treatment-resistant, symptomatic rashes may require EGFRI dose reduction and oral isotretinoin prescription. An acne-like rash of grade 4 warrants discontinuation of EGFRI therapy. All severity types benefit from general measures such as sun protection and the use of gentle soaps and light emollients. The presence of pruritus at any grade can be controlled with oral antihistamines [115,116]. Prophylactic treatment with oral tetracyclines has demonstrated efficacy, and it may be considered in patients starting EGFRI [114]. The final therapeutic practice is adjusted to the individual patient, and the involvement of a multidisciplinary team contributes to a more successful treatment [11,115].

5. Conclusions

Although acne is perceived as a skin condition with easily identifiable characteristics, its distinction from acne-like eruptions may pose a challenge in diagnostics. This group of dermatoses resembling acne vulgaris encloses an extensive number of dermatological conditions, which vary significantly in terms of severity and prevalence. The lesions of acne-like eruptions can manifest as papules, pustules, nodules, or cysts. As opposed to acne, these lesions are not necessarily confined to seborrheic areas and can affect any age group. They may present abruptly and have a monomorphic appearance. Moreover, the presence of comedones is generally uncommon, although they may occur in certain types of acne-like eruptions. Therefore, when evaluating these lesions, it is important to obtain a complete medical history, inquire about concomitant diseases, use of certain products and prescription drugs, exposure to physical and chemical agents, and perform a detailed clinical examination. The implementation of existing knowledge about acne-like eruptions, along with further investigations into the pathophysiology of the conditions that fall under it, is fundamental for achieving an accurate diagnosis and favorable treatment outcomes.

Author Contributions: Conceptualization, E.P. and Z.B.M.; methodology, Z.B.M.; software, E.P. and B.Š.; validation, E.P. and Z.B.M.; formal analysis, E.P. and Z.B.M.; investigation, E.P. and Z.B.M.; resources, L.L.-M. and Z.B.M.; data curation, E.P. and B.Š.; writing—original draft preparation, E.P. and Z.B.M.; writing—review and editing, E.P., L.L.-M., B.Š., and Z.B.M.; visualization, E.P.; supervision, L.L.-M. and Z.B.M.; project administration, E.P. and B.Š. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Layton, A.M.; Thiboutot, D.; Tan, J. Reviewing the Global Burden of Acne: How Could We Improve Care to Reduce the Burden? *Br. J. Dermatol.* **2020**, *184*, 219–225. [CrossRef] [PubMed]
2. Sutaria, A.H.; Masood, S.; Schlessinger, J. Acne Vulgaris. Available online: <https://www.ncbi.nlm.nih.gov/books/NBK459173> (accessed on 9 April 2023).
3. Ogé, L.K.; Broussard, A.; Marshall, M.D. Acne Vulgaris: Diagnosis and Treatment. *Am. Fam. Physician* **2019**, *100*, 475–484. [PubMed]
4. Vos, T.; Flaxman, A.D.; Naghavi, M.; Lozano, R.; Michaud, C.; Ezzati, M.; Shibuya, K.; Salomon, J.A.; Abdalla, S.; Aboyans, V.; et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. *Lancet* **2012**, *380*, 2163–2196. [CrossRef] [PubMed]
5. Hay, R.J.; Johns, N.E.; Williams, H.C.; Bolliger, I.W.; Dellavalle, R.P.; Margolis, D.J.; Marks, R.; Naldi, L.; Weinstock, M.A.; Wulf, S.K.; et al. The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions. *J. Investig. Dermatol.* **2014**, *134*, 1527–1534. [CrossRef]
6. Melnik, B.; Wenchieh, C. Acne and Rosacea. In *Braun-Falco's Dermatology*, 4th ed.; Plewig, G., French, L., Ruzicka, T., Kaufmann, R., Hertl, M., Eds.; Springer: Berlin/Heidelberg, Germany, 2022; pp. 1291–1324.
7. MeSH Browser. Available online: <https://meshb.nlm.nih.gov/record/ui?ui=D017486> (accessed on 10 April 2023).
8. Cheung, M.J.; Taher, M.; Lauzon, G.J. Acneiform facial eruptions: A problem for young women. *Can. Fam. Physician* **2005**, *51*, 527–533.
9. Kuflik, J.H. Acneiform Eruptions: Practice Essentials. Available online: <https://emedicine.medscape.com/article/1072536-differential> (accessed on 10 April 2023).
10. Thiboutot, D.; Zaenglein, A.L. Pathogenesis, Clinical Manifestations, and Diagnosis of Acne Vulgaris. Available online: <https://www.uptodate.com/contents/pathogenesis-clinical-manifestations-and-diagnosis-of-acne-vulgaris> (accessed on 10 April 2023).
11. Dessinioti, C.; Antoniou, C.; Katsambas, A. Acneiform Eruptions. *Clin. Dermatol.* **2014**, *32*, 24–34. [CrossRef]
12. Alia, E.; Feng, H. Rosacea Pathogenesis, Common Triggers, and Dietary Role: The Cause, the Trigger, and the Positive Effects of Different Foods. *Clin. Dermatol.* **2021**, *40*, 122–127. [CrossRef]
13. Marson, J.W.; Baldwin, H.E. Rosacea: A Wholistic Review and Update from Pathogenesis to Diagnosis and Therapy. *Int. J. Dermatol.* **2019**, *59*, e175–e182. [CrossRef]
14. Ahn, C.S.; Huang, W.W. Rosacea Pathogenesis. *Dermatol. Clin.* **2018**, *36*, 81–86. [CrossRef]
15. Kim, H.S. Microbiota in Rosacea. *Am. J. Clin. Dermatol.* **2020**, *21* (Suppl. S1), 25–35. [CrossRef]
16. Ferček, I.; Lugović-Mihić, L.; Tambić-Andrašević, A.; Česić, D.; Grginić, A.G.; Bešlić, I.; Mravak-Stipetić, M.; Mihatov-Štefanović, I.; Buntić, A.-M.; Čivljak, R. Features of the Skin Microbiota in Common Inflammatory Skin Diseases. *Life* **2021**, *11*, 962. [CrossRef] [PubMed]
17. Picardo, M.; Eichenfield, L.F.; Tan, J. Acne and Rosacea. *Dermatol. Ther.* **2017**, *7* (Suppl. S1), 43–52. [CrossRef] [PubMed]
18. Zhang, H.; Tang, K.; Wang, Y.; Fang, R.; Sun, Q. Rosacea Treatment: Review and Update. *Dermatol. Ther.* **2021**, *11*, 13–24. [CrossRef] [PubMed]
19. Parać, E. Acneiform Eruptions. Diploma Thesis, University of Zagreb, School of Medicine, Zagreb, Croatia, 2022. Available online: <https://urn.nsk.hr/urn:nbn:hr:105:662849> (accessed on 7 May 2023).
20. Yun, C.H.; Yun, J.H.; Baek, J.O.; Roh, J.Y.; Lee, J.R. *Demodex* Mite Density Determinations by Standardized Skin Surface Biopsy and Direct Microscopic Examination and Their Relations with Clinical Types and Distribution Patterns. *Ann. Dermatol.* **2017**, *29*, 137–142. [CrossRef]
21. Rather, P.; Hassan, I. Human *Demodex* Mite: The Versatile Mite of Dermatological Importance. *Indian. J. Dermatol.* **2014**, *59*, 60. [CrossRef]
22. Yüksel, S.; Pancar Yüksel, E. Increased *Demodex* Density in Patients Hospitalized for Worsening Heart Failure. *J. Pers. Med.* **2020**, *10*, 39. [CrossRef]

23. Bendezu-Quispe, G.; Rojas-Zevallos, J.; Rosales-Rimache, J. Type 2 Diabetes Mellitus and *Demodex folliculorum* Infestation: A Cross-Sectional Study in Peruvian Patients. *Int. J. Environ. Res. Public Health* **2022**, *19*, 13582. [CrossRef]
24. Toka Özer, T.; Akyürek, Ö.; Durmaz, S. Association between *Demodex folliculorum* and Metabolic Syndrome. *J. Cosmet. Dermatol.* **2020**, *19*, 3145–3149. [CrossRef]
25. Paichitrojjana, A. *Demodex*: The Worst Enemies Are the Ones That Used to Be Friends. *Dermatol. Rep.* **2022**, *14*, 9339. [CrossRef]
26. Paichitrojjana, A. Demodicosis Imitating Acne Vulgaris: A Case Report. *Clin. Cosmet. Investig. Dermatol.* **2022**, *15*, 497–501. [CrossRef]
27. Li, J.; Wei, E.; Reisinger, A.; French, L.E.; Clanner-Engelshofen, B.M.; Reinholz, M. Comparison of Different Anti-*Demodex* Strategies: A Systematic Review and Meta-Analysis. *Dermatology* **2023**, *239*, 12–31. [CrossRef] [PubMed]
28. Mokos, Z.B.; Kummer, A.; Mosler, E.L.; Čeović, R.; Basta-Juzbašić, A. Perioral dermatitis: Still a therapeutic challenge. *Acta Clin. Croat.* **2015**, *54*, 179–185. [PubMed]
29. Searle, T.; Ali, F.R.; Al-Niaimi, F. Perioral Dermatitis: Diagnosis, Proposed Etiologies, and Management. *J. Cosmet. Dermatol.* **2021**, *20*, 3839–3848. [CrossRef]
30. Lugović-Mihić, L.; Špiljak, B.; Blagec, T.; Delaš Aždajić, M.; Franceschi, N.; Gašić, A.; Parać, E. Factors Participating in the Occurrence of Inflammation of the Lips (Cheilitis) and Perioral Skin. *Cosmetics* **2023**, *10*, 9. [CrossRef]
31. Nikolakis, G.; Kokolakis, G.; Kaleta, K.; Wolk, K.; Hunger, R.; Sabat, R.; Zouboulis, C.C. Pathogenese der Hidradenitis Suppurativa/Acne Inversa. *Hautarzt* **2021**, *72*, 658–665. [CrossRef]
32. Goldburg, S.R.; Strober, B.E.; Payette, M.J. Hidradenitis Suppurativa. *J. Am. Acad. Dermatol.* **2020**, *82*, 1045–1058. [CrossRef]
33. Pescitelli, L.; Ricceri, F.; Prignano, F. Hidradenitis Suppurativa and Associated Diseases. *G. Ital. Dermatol. Venereol.* **2018**, *153* (Suppl. S2), 8–17. [CrossRef] [PubMed]
34. Frings, V.G.; Bauer, B.; Glöditzsch, M.; Goebeler, M.; Presser, D. Assessing the psychological burden of patients with hidradenitis suppurativa. *Eur. J. Dermatol.* **2019**, *29*, 294–301.
35. Wieczorek, M.; Walecka, I. Hidradenitis Suppurativa—Known and Unknown Disease. *Reumatologia* **2018**, *56*, 337–339. [CrossRef]
36. Seyed Jafari, S.M.; Hunger, R.E.; Schlapbach, C. Hidradenitis Suppurativa: Current Understanding of Pathogenic Mechanisms and Suggestion for Treatment Algorithm. *Front. Med.* **2020**, *7*, 68. [CrossRef]
37. Ogunbiyi, A. Pseudofolliculitis Barbae; Current Treatment Options. *Clin. Cosmet. Investig. Dermatol.* **2019**, *12*, 241–247. [CrossRef] [PubMed]
38. Goldstein, B.G.; Goldstein, A.O. *Pseudofolliculitis Barbae*; Post, T.W., Ed.; UpToDate: Waltham, MA, USA, 2022.
39. Kelly, A.P. Pseudofolliculitis Barbae and Acne Keloidalis Nuchae. *Dermatol. Clin.* **2003**, *21*, 645–653. [CrossRef] [PubMed]
40. Dalia, Y.; Khatib, J.; Odens, H.; Patel, T. A Review of Treatments of Pseudofolliculitis Barbae. *Clin. Exp. Dermatol.* **2023**, *48*, 591–598. [CrossRef] [PubMed]
41. Ribera, M.; Fernández-Chico, N.; Casals, M. Pseudofolliculitis de la barba [Pseudofolliculitis barbae]. *Actas Dermo-Sifiliográficas* **2010**, *101*, 749–757. [CrossRef]
42. Katoh, M.; Nomura, T.; Miyachi, Y.; Kabashima, K. Eosinophilic Pustular Folliculitis: A Review of the Japanese Published Works. *J. Dermatol.* **2012**, *40*, 15–20. [CrossRef]
43. Nomura, T.; Katoh, M.; Yamamoto, Y.; Miyachi, Y.; Kabashima, K. Eosinophilic Pustular Folliculitis: A Proposal of Diagnostic and Therapeutic Algorithms. *J. Dermatol.* **2016**, *43*, 1301–1306. [CrossRef]
44. Nervi, S.J.; Schwartz, R.A.; Dmochowski, M. Eosinophilic Pustular Folliculitis: A 40 Year Retrospect. *J. Am. Acad. Dermatol.* **2006**, *55*, 285–289. [CrossRef]
45. Sève, P.; Pacheco, Y.; Durupt, F.; Jamilloux, Y.; Gerfaud-Valentin, M.; Isaac, S.; Bousset, L.; Calender, A.; Androdias, G.; Valeyre, D.; et al. Sarcoidosis: A Clinical Overview from Symptoms to Diagnosis. *Cells* **2021**, *10*, 766. [CrossRef]
46. Caplan, A.; Rosenbach, M.; Imadojemu, S. Cutaneous Sarcoidosis. *Semin. Respir. Crit. Care Med.* **2020**, *41*, 689–699. [CrossRef]
47. Zeichner, J.A. *Acneiform Eruptions in Dermatology: A Differential Diagnosis*; Springer: New York, NY, USA, 2014.
48. Schmieder, S.J.; Harper, C.D.; Schmieder, G.J. Granuloma Annulare. Available online: <https://www.ncbi.nlm.nih.gov/books/NBK459377/> (accessed on 10 April 2023).
49. Joshi, T.P.; Duvic, M. Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options. *Am. J. Clin. Dermatol.* **2021**, *23*, 37–50. [CrossRef]
50. Smith, R. Papular Granuloma Annulare. In *Acneiform Eruptions in Dermatology*; Zeichner, J., Ed.; Springer: New York, NY, USA, 2014; pp. 375–379.
51. Xue, J.; Lam, J.M. Granuloma Annulare. *Paediatr. Child. Health* **2019**, *24*, 366–367. [CrossRef] [PubMed]
52. Rubin, C.B.; Rosenbach, M. Granuloma annulare: A retrospective series of 133 patients. *Cutis* **2019**, *103*, 102–106. [PubMed]
53. Wang, J.; Khachemoune, A. Granuloma Annulare: A Focused Review of Therapeutic Options. *Am. J. Clin. Dermatol.* **2017**, *19*, 333–344. [CrossRef]
54. Tambe, S.; Jerajani, H.; Pund, P. Granulomatous Periorificial Dermatitis Effectively Managed with Oral Isotretinoin. *Indian Dermatol. Online J.* **2018**, *9*, 68–70. [CrossRef]
55. Al-Qassabi, A.-M.; Al-Busaidi, K.; Al Baccouche, K.; Al Ismaili, A. Granulomatous Periorificial Dermatitis in an Adult: A Case Report with Review of Literature. *Sultan Qaboos Univ. Med. J.* **2020**, *20*, 100–103. [CrossRef] [PubMed]
56. Chintagunta, S.R.; Manchala, S.; Arakkal, G. Granulomatous periorificial dermatitis in an adult: A rare case report. *J. Dr. NTR Univ. Health Sci.* **2018**, *7*, 143. [CrossRef]

57. Fakh, A.; Makhoul, R.; Grozdev, I. Childhood Granulomatous Periorificial Dermatitis: Case Report and Review of the Literature. *Dermatol. Online J.* **2020**, *26*, 13030. [[CrossRef](#)]
58. Rodriguez-Garijo, N.; Querol-Cisneros, E.; Tomas-Velazquez, A.; Estenaga, A.; Moreno-Artero, E.; Idoate, M.A.; Paricio, J.J.; España, A. Recalcitrant Granulomatous Periorificial Dermatitis with Good Response to Low-Dose Oral Isotretinoin. *Pediatr. Dermatol.* **2019**, *36*, 980–981. [[CrossRef](#)] [[PubMed](#)]
59. Lin, H.S.; Lin, P.T.; Tsai, Y.S.; Wang, S.H.; Chi, C.C. Interventions for bacterial folliculitis and boils (furuncles and carbuncles). *Cochrane Database Syst. Rev.* **2021**, *2*, CD013099. [[CrossRef](#)]
60. Lugović-Mihić, L.; Barisić, F.; Bulat, V.; Buljan, M.; Situm, M.; Bradić, L.; Mihić, J. Differential diagnosis of the scalp hair folliculitis. *Acta Clin. Croat* **2011**, *50*, 395–402.
61. Laureano, A.C.; Schwartz, R.A.; Cohen, P.J. Facial Bacterial Infections: Folliculitis. *Clin. Dermatol.* **2014**, *32*, 711–714. [[CrossRef](#)] [[PubMed](#)]
62. Lawrence, H.S.; Nopper, A.J. Superficial Bacterial Skin Infections and Cellulitis. In *Principles and Practice of Pediatric Infectious Diseases*, 5th ed.; Long, S.S., Prober, C.G., Fischer, M., Eds.; Elsevier—Health Sciences Division: Philadelphia, PA, USA, 2018; pp. 436–444.
63. Plewig, G.; Jansen, T. Acneiform Dermatoses. *Dermatology* **1998**, *196*, 102–107. [[CrossRef](#)] [[PubMed](#)]
64. Böni, R.; Nehrhoff, B. Treatment of Gram-Negative Folliculitis in Patients with Acne. *Am. J. Clin. Dermatol.* **2003**, *4*, 273–276. [[PubMed](#)]
65. Vlachos, C.; Henning, M.A.S.; Gaitanis, G.; Faergemann, J.; Saunte, D.M. Critical Synthesis of Available Data in *Malassezia* Folliculitis and a Systematic Review of Treatments. *J. Eur. Acad. Dermatol. Venereol.* **2020**, *34*, 1672–1683. [[CrossRef](#)]
66. Rubenstein, R.M.; Malerich, S.A. *Malassezia* (Pityrosporum) Folliculitis. *J. Clin. Aesthetic Dermatol.* **2014**, *7*, 37–41.
67. Saunte, D.M.L.; Gaitanis, G.; Hay, R.J. *Malassezia*-Associated Skin Diseases, the Use of Diagnostics and Treatment. *Front. Cell. Infect.* **2020**, *10*, 112. [[CrossRef](#)]
68. Malgotra, V.; Singh, H. *Malassezia* (Pityrosporum) Folliculitis Masquerading as Recalcitrant Acne. *Cureus* **2021**, *13*, e13534. [[CrossRef](#)]
69. Spornovasilis, N.; Psychogiou, M.; Poulakou, G. Skin Manifestations of *Pseudomonas aeruginosa* Infections. *Curr. Opin. Infect. Dis.* **2021**, *34*, 72–79. [[CrossRef](#)]
70. Ratnam, S.; Hogan, K.; March, S.B.; Butler, R.W. Whirlpool-Associated Folliculitis Caused by *Pseudomonas aeruginosa*: Report of an Outbreak and Review. *J. Clin. Microbiol.* **1986**, *23*, 655–659. [[CrossRef](#)]
71. Toner, C.B. *Pseudomonas Folliculitis*; Elston, D.M., Ed.; Medscape: New York, NY, USA, 2020.
72. Revanker, S.G. Sporotrichosis—Infectious Diseases. Available online: <https://www.msmanuals.com/professional/infectious-diseases/fungi/sporotrichosis> (accessed on 10 April 2023).
73. Sizar, O.; Talati, R. Sporotrichosis. Available online: <https://www.ncbi.nlm.nih.gov/books/NBK532255> (accessed on 10 April 2023).
74. Mahlberg, M.J.; Patel, R.; Rosenman, K.; Cheung, W.; Wang, N.; Sanchez, M. Fixed Cutaneous Sporotrichosis. *Dermatol. Online J.* **2009**, *15*, 5. [[CrossRef](#)]
75. Kusuhara, M.; Hachisuka, H.; Sasai, Y. Statistical Survey of 150 Cases with Sporotrichosis. *Mycopathologia* **1988**, *102*, 129–133. [[CrossRef](#)] [[PubMed](#)]
76. Garcia, S.C.G.; Alanis, J.C.S.; Flores, M.G.; Gonzalez, S.E.G.; Cabrera, L.V.; Candiani, J.O. Coccidioidomycosis and the Skin: A Comprehensive Review. *An. Bras. Dermatol.* **2015**, *90*, 610–619. [[CrossRef](#)] [[PubMed](#)]
77. Ocampo-Garza, J.; Castrejón-Pérez, A.D.; Gonzalez-Saldivar, G.; Ocampo-Candiani, J. Cutaneous Coccidioidomycosis: A Great Mimicker. *BMJ Case Rep.* **2015**, *2015*, bcr2015211680. [[CrossRef](#)] [[PubMed](#)]
78. Lambert, W.C.; Bagley, M.P.; Khan, Y.; Schwartz, R.A. Pustular acneiform secondary syphilis. *Cutis* **1986**, *37*, 69–70. [[PubMed](#)]
79. Harden, D. Papular and Nodular Lesions of the Scalp, Face, and Neck. *Arch. Dermatol.* **1997**, *133*, 1027. [[CrossRef](#)] [[PubMed](#)]
80. Blaess, M.; Kaiser, L.; Sommerfeld, O.; Csuk, R.; Deigner, H.-P. Drug Triggered Pruritus, Rash, Papules, and Blisters—Is AGEp a Clash of an Altered Sphingolipid-Metabolism and Lysosomotropism of Drugs Accumulating in the Skin? *Lipids Health Dis.* **2021**, *20*, 156. [[CrossRef](#)] [[PubMed](#)]
81. Hjorth, N.; Sjolín, K.E.; Sylvest, B.; Thomsen, K. Acne Aestivalis—Mallorca Acne. *Acta Derm. Venereol.* **1972**, *52*, 61–63. [[CrossRef](#)]
82. Jones, C.; Bleehe, S.S. Acne Induced by PUVA Treatment. *BMJ* **1977**, *2*, 866. [[CrossRef](#)]
83. Mazhar, M.; Simpson, M.; Marathe, K. Inner Thigh Friction as a Cause of Acne Mechanica. *Pediatr. Dermatol.* **2019**, *36*, 546–547. [[CrossRef](#)]
84. Freiman, A. Sports Dermatology Part 1: Common Dermatoses. *CMAJ* **2004**, *171*, 851–853. [[CrossRef](#)]
85. Kirkland, R.; Adams, B.B. Dermatological Problems in the Football Player. *Int. J. Dermatol.* **2006**, *45*, 927–932. [[CrossRef](#)] [[PubMed](#)]
86. Knierim, C.; Goertz, W.; Reifenberger, J.; Homey, B.; Meller, S. Geigerknoten. *Hautarzt* **2013**, *64*, 724–726. [[CrossRef](#)]
87. Kligman, A.M. Acne Cosmetica. *Arch. Dermatol.* **1972**, *106*, 843–850. [[CrossRef](#)] [[PubMed](#)]
88. Plewig, G. Pomade Acne. *Arch. Dermatol.* **1970**, *101*, 580–584. [[CrossRef](#)] [[PubMed](#)]
89. Martin, W.M.C.; Bardsley, A.F. The Comedo Skin Reaction to Radiotherapy. *Br. J. Radiol.* **2002**, *75*, 478–481. [[CrossRef](#)] [[PubMed](#)]
90. Hubiche, T.; Sibaud, V. Localized Acne Induced by Radiation Therapy. *Dermatol. Online J.* **2014**, *20*, 21545. [[CrossRef](#)]
91. Paganelli, A.; Mandel, V.D.; Kaleci, S.; Pellacani, G.; Rossi, E. Favre–Racouchot Disease: Systematic Review and Possible Therapeutic Strategies. *J. Eur. Acad. Dermatol. Venereol.* **2018**, *33*, 32–41. [[CrossRef](#)]

92. Sonthalia, S.; Arora, R.; Chhabra, N.; Khopkar, U. Favre-Racouchot Syndrome. *Indian Dermatol. Online J.* **2014**, *5*, 128. [[CrossRef](#)]
93. Platsidaki, E.; Markantoni, V.; Balamoti, E.; Kouris, A.; Rigopoulos, D.; Kontochristopoulos, G. Combination of 30% Salicylic Acid Peels and Mechanical Comedo Extraction for the Treatment of Favre-Racouchot Syndrome. *Acta Dermatovenerol. Croat.* **2019**, *27*, 42–43.
94. Schlessinger, D.I.; Robinson, C.A.; Schlessinger, J. Chloracne. Available online: <https://www.ncbi.nlm.nih.gov/books/NBK459189/> (accessed on 10 April 2023).
95. Dyall-Smith, D. Halogenoderma. Available online: <https://dermnetz.org/topics/halogenoderma> (accessed on 18 May 2023).
96. Ju, Q.; Zouboulis, C.C.; Xia, L. Environmental Pollution and Acne-Chloracne. *Dermato-Endocrinology* **2009**, *1*, 125–128. [[CrossRef](#)]
97. Eskenazi, B.; Warner, M.; Brambilla, P.; Signorini, S.; Ames, J.; Mocarelli, P. The Seveso accident: A look at 40 years of health research and beyond. *Environ. Int.* **2018**, *121 Pt 1*, 71–84. [[CrossRef](#)] [[PubMed](#)]
98. Onozuka, D.; Nakamura, Y.; Tsuji, G.; Furue, M. Mortality in Yusho Patients Exposed to Polychlorinated Biphenyls and Polychlorinated Dibenzofurans: A 50-Year Retrospective Cohort Study. *Environ. Health* **2020**, *19*, 119. [[CrossRef](#)] [[PubMed](#)]
99. Carpenter, D.O. Polychlorinated Biphenyls (PCBs): Routes of Exposure and Effects on Human Health. *Rev. Environ. Health* **2006**, *21*, 1–24. [[CrossRef](#)]
100. Pelclová, D.; Urban, P.; Preiss, J.; Lukáš, E.; Fenclová, Z.; Navrátil, T.; Dubská, Z.; Senholdová, Z. Adverse Health Effects in Humans Exposed to 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD). *Rev. Environ. Health* **2006**, *21*, 119–138. [[CrossRef](#)] [[PubMed](#)]
101. Demir, B.; Cicek, D. Occupational Acne. In *Acne and Acneiform Eruptions*; Kartal, S.P., Gönül, M., Eds.; IntechOpen: London, UK, 2017; pp. 53–67.
102. Tindall, J.P. Chloracne and Chloracnegens. *J. Am. Acad. Dermatol.* **1985**, *13*, 539–558. [[CrossRef](#)]
103. Panteleyev, A.A.; Bickers, D.R. Dioxin-Induced Chloracne—Reconstructing the Cellular and Molecular Mechanisms of a Classic Environmental Disease. *Exp. Dermatol.* **2006**, *15*, 705–730. [[CrossRef](#)] [[PubMed](#)]
104. Kokelj, F. Occupational Acne. *Clin. Dermatol.* **1992**, *10*, 213–217. [[CrossRef](#)]
105. Moustafa, G.-A.; Xanthopoulou, E.; Riza, E.; Linos, A. Skin Disease after Occupational Dermal Exposure to Coal Tar: A Review of the Scientific Literature. *Int. J. Dermatol.* **2015**, *54*, 868–879. [[CrossRef](#)]
106. Zorba, E.; Karpouzis, A.; Zorbas, A.; Bazas, T.; Zorbas, S.; Alexopoulos, E.; Zorbas, I.; Kouskoukis, K.; Konstandinidis, T. Occupational Dermatoses by Type of Work in Greece. *Saf. Health Work* **2013**, *4*, 142–148. [[CrossRef](#)]
107. Brunner, M.J.; Riddell, J.M., Jr.; Best, W.R. Cutaneous side effects of ACTH cortisone and pregnenolone therapy. *J. Investig. Dermatol.* **1951**, *16*, 205–210. [[CrossRef](#)]
108. Hurwitz, R.M. Steroid acne. *J. Am. Acad. Dermatol.* **1989**, *21*, 1179–1181. [[CrossRef](#)] [[PubMed](#)]
109. Gloor, M.; Mildenerger, K.H. On the influence of an external therapy with dexamethasone-21-sodium-m-sulfobenzoate on the amount of free fatty acids in the skin surface lipids. *Arch. Dermatol. Res.* **1978**, *261*, 33–38. [[CrossRef](#)] [[PubMed](#)]
110. Do, H.K.; Ezra, N.; Wolverton, S.E. Drug-Induced Acneiform Eruptions. In *Acneiform Eruptions in Dermatology*; Zeichner, J., Ed.; Springer: New York, NY, USA, 2014; pp. 389–404.
111. Ayati, A.; Moghimi, S.; Salarinejad, S.; Safavi, M.; Pouramiri, B.; Foroumadi, A. A Review on Progression of Epidermal Growth Factor Receptor (EGFR) Inhibitors as an Efficient Approach in Cancer Targeted Therapy. *Bioorg. Chem.* **2020**, *99*, 103811. [[CrossRef](#)] [[PubMed](#)]
112. Segaert, S.; Van Cutsem, E. Clinical Signs, Pathophysiology and Management of Skin Toxicity during Therapy with Epidermal Growth Factor Receptor Inhibitors. *Ann. Oncol.* **2005**, *16*, 1425–1433. [[CrossRef](#)]
113. Fabbrocini, G.; Panariello, L.; Caro, G.; Cacciapuoti, S. Acneiform Rash Induced by EGFR Inhibitors: Review of the Literature and New Insights. *Ski. Appendage Disord.* **2015**, *1*, 31–37. [[CrossRef](#)]
114. Gorji, M.; Joseph, J.; Pavlakis, N.; Smith, S.D. Prevention and Management of Acneiform Rash Associated with EGFR Inhibitor Therapy: A Systematic Review and Meta-Analysis. *Asia-Pac. J. Clin. Oncol.* **2022**, *18*, 526–539. [[CrossRef](#)]
115. Potthoff, K.; Hofheinz, R.; Hassel, J.C.; Volkenandt, M.; Lordick, F.; Hartmann, J.T.; Karthaus, M.; Riess, H.; Lipp, H.P.; Hauschild, A.; et al. Interdisciplinary Management of EGFR-Inhibitor-Induced Skin Reactions: A German Expert Opinion. *Ann. Oncol.* **2011**, *22*, 524–535. [[CrossRef](#)]
116. Beech, J.; Germetaki, T.; Judge, M.; Paton, N.; Collins, J.; Garbutt, A.; Braun, M.; Fenwick, J.; Saunders, M.P. Management and Grading of EGFR Inhibitor-Induced Cutaneous Toxicity. *Future Oncol.* **2018**, *14*, 2531–2541. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.